Viral vector delivery of neurotrophic factors for Parkinson's disease therapy

Expert Reviews in Molecular Medicine

Volumn 17, Issue , 2015, Pages

  Kelly, Martin J ^a   O'Keeffe, Gerard W ^a   Sullivan, Aideen M ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CATECHOL METHYLTRANSFERASE INHIBITOR; CEREBRAL DOPAMINE NEUROTROPHIC FACTOR; DOPA DECARBOXYLASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUTAMATE DECARBOXYLASE; GROWTH DIFFERENTIATION FACTOR 5; LENTIVIRUS VECTOR; LEVODOPA; LIATERMIN; MESENCEPHALIC ASTROCYTE DERIVED NEUROTROPHIC FACTOR; MONOAMINE OXIDASE B INHIBITOR; NEUROTROPHIC FACTOR; NEURTURIN; PARVOVIRUS VECTOR; PLACEBO; UNCLASSIFIED DRUG; VIRUS VECTOR; DOPAMINE; NERVE GROWTH FACTOR;

DEPRESSION; DOPAMINERGIC NERVE CELL; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG TRANSPORT; HUMAN; INTRASTRIATAL DRUG ADMINISTRATION; LEVODOPA-INDUCED DYSKINESIA; LOSS OF APPETITE; LOW DRUG DOSE; MOTOR DYSFUNCTION; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARESTHESIA; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; ADENOVIRIDAE; ANIMAL; DEPENDOPARVOVIRUS; GENE THERAPY; GENE VECTOR; GENETICS; LENTIVIRINAE; METABOLISM; PATHOLOGY;

ADENOVIRIDAE; ANIMALS; DEPENDOVIRUS; DOPAMINE; DOPAMINERGIC NEURONS; GENETIC THERAPY; GENETIC VECTORS; HUMANS; LENTIVIRUS; NERVE GROWTH FACTORS; PARKINSON DISEASE;

EID: 84942430232     PISSN: 14623994     EISSN: None     Source Type: Journal    
DOI: 10.1017/erm.2015.6     Document Type: Review

References (129)

1. Gordon K.J. and Blobe G.C. (2008) Role of transforming growth factor-beta superfamily signaling pathways in human disease. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1782, 197-228
2. Saarma M. (2000) GDNF-A stranger in the TGF-beta superfamily? European Journal of Biochemistry 267, 6968-6971
3. Sariola H. and Saarma M. (2003) Novel functions and signaling pathways for GDNF. Journal of Cell Science 116, 3855-3862
4. Sullivan A.M. and Toulouse A. (2011) Neurotrophic factors for the treatment of Parkinson's disease. Cytokine & Growth Factor Reviews 22, 157-165
5. Lindholm P. and Saarma M. (2010) Novel CDNF/MANF family of neurotrophic factors. Developmental Neurobiology 70, 360-371
6. Hegarty S.V., O'Keeffe G.W. and Sullivan A.M. (2013) BMPSmad 1/5/8 signalling in the development of the nervous system. Progress in Neurobiology 109, 28-41
7. Nishitoh H. et al. (1996) Identification of type I and type II serine/threonine kinase receptors for growth/differentiation factor-5. Journal of Biological Chemistry 271, 21345-21352
8. Toulouse A. and Sullivan A.M. (2008) Progress in Parkinson's disease-where do we stand? Progress in Neurobiology 85, 376-392
9. Yokochi M. (2009) Reevaluation of levodopa therapy for the treatment of advanced Parkinson's disease. Parkinsonism & Related Disorders 15(Suppl 1), S25-S30
10. Beric A. et al. (2001) Complications of deep brain stimulation surgery. Stereotactic and Functional Neurosurgery 77, 73-78
11. Samii A., Nutt J.G. and Ransom B.R. (2004) Parkinson's disease. Lancet 363, 1783-1793
12. Krieglstein K. et al. (1995) TGF-beta superfamily members promote survival of midbrain dopaminergic neurons and protect them against MPP+ toxicity. EMBO Journal 14, 736-742
13. Lin L.F. et al. (1993) GDNF: A glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260, 1130-1132
14. Widmer H.R. et al. (2000) Glial cell line-derived neurotrophic factor stimulates the morphological differentiation of cultured ventral mesencephalic calbindin-And calretinin-expressing neurons. Experimental Neurology 164, 71-81
15. Hou J.G., Lin L.F. and Mytilineou C. (1996) Glial cell linederived neurotrophic factor exerts neurotrophic effects on dopaminergic neurons in vitro and promotes their survival and regrowth after damage by 1-methyl-4-phenylpyridinium. Journal of Neurochemistry 66, 74-82
16. Eggert K. et al. (1999) Glial cell line-derived neurotrophic factor protects dopaminergic neurons from 6-hydroxydopamine toxicity in vitro. Neuroscience Letters 269, 178-182
17. Bowenkamp K.E. et al. (1995) Glial cell line-derived neurotrophic factor supports survival of injured midbrain dopaminergic neurons. Journal of Comparative Neurology 355, 479-489
18. Hoffer B.J. et al. (1994) Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo. Neuroscience Letters 182, 107-111
19. Kearns C.M. and Gash D.M. (1995) GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo. Brain Research 672, 104-111
20. Sauer H., Rosenblad C. and Bjorklund A. (1995) Glial cell line-derived neurotrophic factor but not transforming growth factor beta 3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion. Proceedings of the National Academy of Sciences of the United States of America 92, 8935-8939
21. Shults C.W., Kimber T. and Martin D. (1996) Intrastriatal injection of GDNF attenuates the effects of 6-hydroxydopamine. Neuroreport 7, 627-631
22. Sullivan A.M., Opacka-Juffry J. and Blunt S.B. (1998) Longterm protection of the rat nigrostriatal dopaminergic system by glial cell line-derived neurotrophic factor against 6-hydroxydopamine in vivo. European Journal of Neuroscience 10, 57-63
23. Bjorklund A. et al. (2000) Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model. Brain Research 886, 82-98
24. Tomac A. et al. (1995) Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 373, 335-339
25. Rosenblad C., Martinez-Serrano A. and Bjorklund A. (1998) Intrastriatal glial cell line-derived neurotrophic factor promotes sprouting of spared nigrostriatal dopaminergic afferents and induces recovery of function in a rat model of Parkinson's disease. Neuroscience 82, 129-137
26. Aoi M. et al. (2000) The effect of intrastriatal single injection of GDNF on the nigrostriatal dopaminergic system in hemiparkinsonian rats: behavioral and histological studies using two different dosages. Neuroscience Research 36, 319-325
27. Granholm A.C. et al. (1997) Glial cell line-derived neurotrophic factor improves survival of ventral mesencephalic grafts to the 6-hydroxydopamine lesioned striatum. Experimental Brain Research 116, 29-38
28. Apostolides C. et al. (1998) Glial cell line-derived neurotrophic factor improves intrastriatal graft survival of stored dopaminergic cells. Neuroscience 83, 363-372
29. Sullivan A.M., Pohl J. and Blunt S.B. (1998) Growth/differentiation factor 5 and glial cell line-derived neurotrophic factor enhance survival and function of dopaminergic grafts in a rat model of Parkinson's disease. European Journal of Neuroscience 10, 3681-3688
30. Yurek D.M. (1998) Glial cell line-derived neurotrophic factor improves survival of dopaminergic neurons in transplants of fetal ventral mesencephalic tissue. Experimental Neurology 153, 195-202
31. Gash D.M. et al. (1996) Functional recovery in parkinsonian monkeys treated with GDNF. Nature 380, 252-255
32. Gerhardt G.A. et al. (1999) GDNF improves dopamine function in the substantia nigra but not the putamen of unilateral MPTP-lesioned rhesus monkeys. Brain Research 817, 163-171
33. Grondin R. et al. (2002) Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. Brain 125, 2191-2201
34. Iravani M.M. et al. (2001) GDNF reverses priming for dyskinesia in MPTP-Treated, L-DOPA-primed common marmosets. European Journal of Neuroscience 13, 597-608
35. Maswood N. et al. (2002) Effects of chronic intraputamenal infusion of glial cell line-derived neurotrophic factor (GDNF) in aged Rhesus monkeys. Neurobiology of Aging 23, 881-889
36. Miyoshi Y. et al. (1997) Glial cell line-derived neurotrophic factor-levodopa interactions and reduction of side effects in parkinsonian monkeys. Annals of Neurology 42, 208-214
37. Nutt J.G. et al. (2003) Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 60, 69-73
38. Gill S.S. et al. (2003) Direct brain infusion of glial cell linederived neurotrophic factor in Parkinson disease. Nature Medicine 9, 589-595
39. Patel N.K. et al. (2005) Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: A two-year outcome study. Annals of Neurology 57, 298-302
40. Slevin J.T. et al. (2005) Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. Journal of Neurosurgery 102, 216-222
41. Lang A.E. et al. (2006) Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Annals of Neurology 59, 459-466
42. Tatarewicz S.M. et al. (2007) Development of a maturing Tcell-mediated immune response in patients with idiopathic Parkinson's disease receiving r-metHuGDNF via continuous intraputaminal infusion. Journal of Clinical Immunology 27, 620-627
43. Kotzbauer P.T. et al. (1996) Neurturin, a relative of glial-cellline-derived neurotrophic factor. Nature 384, 467-470
44. Horger B.A. et al. (1998) Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons. Journal of Neuroscience 18, 4929-4937
45. Akerud P. et al. (1999) Differential effects of glial cell linederived neurotrophic factor and neurturin on developing and adult substantia nigra dopaminergic neurons. Journal of Neurochemistry 73, 70-78
46. Rosenblad C. et al. (1999) Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle. European Journal of Neuroscience 11, 1554-1566
47. Oiwa Y. et al. (2002) Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease. Brain Research 947, 271-283
48. Grondin R. et al. (2008) Intraputamenal infusion of exogenous neurturin protein restores motor and dopaminergic function in the globus pallidus of MPTP-lesioned rhesus monkeys. Cell Transplantation 17, 373-381
49. Petrova P. et al. (2003) MANF: A new mesencephalic, astrocyte-derived neurotrophic factor with selectivity for dopaminergic neurons. Journal of Molecular Neuroscience 20, 173-188
50. Lindholm P. et al. (2007) Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo. Nature 448, 73-77
51. Parkash V. et al. (2009) The structure of the conserved neurotrophic factors MANF and CDNF explains why they are bifunctional. Protein Engineering Design and Selection 22, 233-241
52. Airavaara M. et al. (2012) CDNF protects the nigrostriatal dopamine system and promotes recovery after MPTP treatment in mice. Cell Transplantation 21, 1213-1223
53. Voutilainen M.H. et al. (2011) Chronic infusion of CDNF prevents 6-OHDA-induced deficits in a rat model of Parkinson's disease. Experimental Neurology 228, 99-108
54. Bäck S. et al. (2013) Gene therapy with AAV2-CDNF provides functional benefits in a rat model of Parkinson's disease. Brain and Behaviour 3, 75-88
55. Ren X. et al. (2013) AAV2-mediated striatum delivery of human CDNF prevents the deterioration of midbrain dopamine neurons in a 6-hydroxydopamine induced parkinsonian rat model. Experimental Neurology 248, 148-156
56. Krieglstein K. et al. (1995) Trophic and protective effects of growth/differentiation factor 5, a member of the transforming growth factor-beta superfamily, on midbrain dopaminergic neurons. Journal of Neuroscience Research 42, 724-732
57. O'Keeffe G.W., Dockery P. and Sullivan A.M. (2004) Effects of growth/differentiation factor 5 on the survival and morphology of embryonic rat midbrain dopaminergic neurones in vitro. Journal of Neurocytology 33, 479-488
58. Costello D.J. et al. (2012) Transplantation of novel human GDF5-expressing CHO cells is neuroprotective in models of Parkinson's disease. Journal of Cellular and Molecular Medicine 16, 2451-2460
59. Hegarty S.V., Sullivan A.M. and O'Keeffe G.W. (2013) BMP2 and GDF5 induce neuronal differentiation through a Smad dependant pathway in a model of human midbrain dopaminergic neurons. Molecular and Cellular Neuroscience 56, 263-271
60. Hegarty S.V. et al. (2014) Canonical BMP-Smad signalling promotes neurite growth in rat midbrain dopaminergic neurons. Neuromolecular Medicine 16, 473-489
61. Sullivan A.M. et al. (1997) Growth/differentiation factor 5 protects nigrostriatal dopaminergic neurones in a rat model of Parkinson's disease. Neuroscience Letters 233, 73-76
62. Sullivan A.M. et al. (1999) Neuroprotective effects of growth/differentiation factor 5 depend on the site of administration. Brain Research 818, 176-179
63. Hurley F.M., Costello D.J. and Sullivan A.M. (2004) Neuroprotective effects of delayed administration of growth/differentiation factor-5 in the partial lesion model of Parkinson's disease. Experimental Neurology 185, 281-289
64. LeWitt P.A. et al. (2011) AAV2-GAD gene therapy for advanced Parkinson's disease: A double-blind, sham-surgery controlled, randomised trial. Lancet Neurology 10, 309-319
65. Karra D. and Dahm R. (2010) Transfection techniques for neuronal cells. Journal of Neuroscience 30, 6171-6177
66. White E. (2012) Molecular neurosurgery: vectors and vector delivery strategies. British Journal of Neurosurgery 26, 798-808
67. Ginn S.L. et al. (2013) Gene therapy clinical trials worldwide to 2012-An update. Journal of Gene Medicine 15, 65-77
68. Choi-Lundberg D.L. et al. (1997) Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science 275, 838-841
69. Mandel R.J. et al. (1997) Midbrain injection of recombinant adeno-Associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats. Proceedings of the National Academy of Sciences of the United States of America 94, 14083-14088
70. Balemans W. and Van Hul W. (2002) Extracellular regulation of BMP signaling in vertebrates: A cocktail of modulators. Developmental Biology 250, 231-250
71. Bilang-Bleuel A. et al. (1997) Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease. Proceedings of the National Academy of Sciences of the United States of America 94, 8818-8823
72. Choi-Lundberg D.L. et al. (1998) Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor. Experimental Neurology 154, 261-275
73. Lapchak P.A. et al. (1997) Adenoviral vector-mediated GDNF gene therapy in a rodent lesion model of late stage Parkinson's disease. Brain Research 777, 153-160
74. Kozlowski D.A. et al. (2000) Delivery of a GDNF gene into the substantia nigra after a progressive 6-OHDA lesion maintains functional nigrostriatal connections. Experimental Neurology 166, 1-15
75. Kojima H. et al. (1997) Adenovirus-mediated transduction with human glial cell line-derived neurotrophic factor gene prevents 1-methyl-4-phenyl-1, 2, 3, 6-Tetrahydropyridine-induced dopamine depletion in striatum of mouse brain. Biochemical and Biophysical Research Communications 238, 569-573
76. Kirik D. et al. (2000) Long-Term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. Journal of Neuroscience 20, 4686-4700
77. Eslamboli A. et al. (2003) Recombinant adeno-Associated viral vector (rAAV) delivery of GDNF provides protection against 6-OHDA lesion in the common marmoset monkey (Callithrix jacchus). Experimental Neurology 184, 536-548
78. Bensadoun J.C. et al. (2000) Lentiviral vectors as a gene delivery system in the mouse midbrain: cellular and behavioral improvements in a 6-OHDA model of Parkinson's disease using GDNF. Experimental Neurology 164, 15-24
79. Georgievska B. et al. (2002) Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector. Neuroreport 13, 75-82
80. Kordower J.H. et al. (2000) Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290, 767-773
81. Dowd E. et al. (2005) Lentivector-mediated delivery of GDNF protects complex motor functions relevant to human Parkinsonism in a rat lesion model. European Journal of Neuroscience 22, 2587-2595
82. Brizard M. et al. (2006) Functional reinnervation from remaining DA terminals induced by GDNF lentivirus in a rat model of early Parkinson's disease. Neurobiology of Disease 21, 90-101
83. DecressacM. et al. (2011) GDNF fails to exert neuroprotection in a rat alpha-synuclein model of Parkinson's disease. Brain 134, 2302-2311
84. Bekris L.M., Mata I.F. and Zabetian C.P. (2010) The genetics of Parkinson disease. Journal of Geriatric Psychiatry and Neurology 23, 228-242
85. Deng H. and Yuan L. (2014) Genetic variants and animal models in SNCA and Parkinson disease. Ageing Research Reviews 15C, 161-176
86. Ulusoy A. et al. (2010) Viral vector-mediated overexpression of alpha-synuclein as a progressive model of Parkinson's disease. Progress in Brain Research 184, 89-111
87. Decressac M. et al. (2012) alpha-Synuclein-induced downregulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons. Science Translational Medicine 4, 163ra156
88. Eberling J.L. et al. (2009) Functional effects of AAV2-GDNF on the dopaminergic nigrostriatal pathway in parkinsonian rhesus monkeys. Human Gene Therapy 20, 511-518
89. Johnston L.C. et al. (2009) Clinically relevant effects of convection-enhanced delivery of AAV2-GDNF on the dopaminergic nigrostriatal pathway in aged rhesus monkeys. Human Gene Therapy 20, 497-510
90. Kells A.P. et al. (2010) Regeneration of the MPTP-lesioned dopaminergic system after convection-enhanced delivery of AAV2-GDNF. Journal of Neuroscience 30, 9567-9577
91. Richardson R.M. et al. (2011) Interventional MRI-guided putaminal delivery of AAV2-GDNF for a planned clinical trial in Parkinson's disease. Molecular Therapy 19, 1048-1057
92. Su X. et al. (2009) Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys. Human Gene Therapy 20, 1627-1640
93. Su X. et al. (2010) Real-Time MR imaging with Gadoteridol predicts distribution of transgenes after convection-enhanced delivery of AAV2 vectors. Molecular Therapy 18, 1490-1495
94. Salegio E.A. et al. (2012) Guided delivery of adeno-Associated viral vectors into the primate brain. Advanced Drug Delivery Reviews 64, 598-604
95. Bobo R.H. et al. (1994) Convection-enhanced delivery of macromolecules in the brain. Proceedings of the National Academy of Sciences of the United States of America 91, 2076-2080
96. Manfredsson F.P. et al. (2009) Tight Long-Term dynamic doxycycline responsive nigrostriatal GDNF using a single rAAV vector. Molecular Therapy 17, 1857-1867
97. Manfredsson F.P. et al. (2009) Nigrostriatal rAAV-mediated GDNF overexpression induces robust weight loss in a rat model of age-related obesity. Molecular Therapy 17, 980-991
98. Gimenez F. et al. (2011) Image-guided convection-enhanced delivery of GDNF protein into monkey putamen. NeuroImage 54(Suppl 1), S189-S195
99. Richardson R.M. et al. (2011) Novel platform for MRI-guided convection-enhanced delivery of therapeutics: preclinical validation in nonhuman primate brain. Stereotactic and Functional Neurosurgery 89, 141-151
100. Krauze M.T. et al. (2005) Reflux-free cannula for convectionenhanced high-speed delivery of therapeutic agents. Journal of Neurosurgery 103, 923-929
101. Sanftner L.M. et al. (2005) AAV2-mediated gene delivery to monkey putamen: evaluation of an infusion device and delivery parameters. Experimental Neurology 194, 476-483
102. Yin D., Forsayeth J. and Bankiewicz K.S. (2010) Optimized cannula design and placement for convection-enhanced delivery in rat striatum. Journal of Neuroscience Methods 187, 46-51
103. Yin D. et al. (2011) Optimal region of the putamen for imageguided convection-enhanced delivery of therapeutics in human and non-human primates. NeuroImage 54(Suppl 1), S196-S203
104. Hadaczek P. et al. (2011) Evaluation of an AAV2-based rapamycin-regulated glial cell line-derived neurotrophic factor (GDNF) expression vector system. PloS ONE 6, e27728
105. Fjord-Larsen L. et al. (2005) Efficient in vivo protection of nigral dopaminergic neurons by lentiviral gene transfer of a modified Neurturin construct. Experimental Neurology 195, 49-60
106. Bartus R.T. et al. (2011) Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: support for nigral targeting in Parkinson's disease. Neurobiology of Disease 44, 38-52
107. Gasmi M. et al. (2007) AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-Term efficacy and tolerability of CERE-120 for Parkinson's disease. Neurobiology of Disease 27, 67-76
108. Herzog C.D. et al. (2013) Enhanced neurotrophic distribution, cell signaling and neuroprotection following substantia nigral versus striatal delivery of AAV2-NRTN (CERE-120). Neurobiology of Disease 58, 38-48
109. Bartus R.T. et al. (2011) Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains. Movement Disorders 26, 27-36
110. Kordower J.H. et al. (2006) Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTPtreated monkeys. Annals of Neurology 60, 706-715
111. Herzog C.D. et al. (2008) Transgene expression, bioactivity, and safety of CERE-120 (AAV2-neurturin) following delivery to the monkey striatum. Molecular Therapy 16, 1737-1744
112. Herzog C.D. et al. (2007) Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys. Movement Disorders 22, 1124-1132
113. Bartus R.T. et al. (2013) Advancing neurotrophic factors as treatments for age-related neurodegenerative diseases: developing and demonstrating "clinical proof-of-concept" for AAVneurturin (CERE-120) in Parkinson's disease. Neurobiology of Aging 34, 35-61
114. Georgievska B., Kirik D. and Bjorklund A. (2004) Overexpression of glial cell line-derived neurotrophic factor using a lentiviral vector induces time-And dose-dependent downregulation of tyrosine hydroxylase in the intact nigrostriatal dopamine system. Journal of Neuroscience 24, 6437-6445
115. Marks W.J. Jr et al. (2008) Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-Associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: An open-label, phase I trial. Lancet Neurology 7, 400-408
116. Marks W.J. Jr et al. (2010) Gene delivery of AAV2-neurturin for Parkinson's disease: A double-blind, randomised, controlled trial. Lancet Neurology 9, 1164-1172
117. Bartus R.T. et al. (2013) Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients. Neurology 80, 1698-1701
118. Bartus R.T. (2013) CERE-120 (AAV2-NRTN) for the treatment of Parkinson's disease: experience from 4 clinical trials and human autopsy data. Proceedings of the 16th Annual Meeting of the American Society forGene andCell Therapy, Salt Lake City, USA.
119. Bartus R.T., Weinberg M.S. and Samulski R.J. (2014) Parkinson's disease gene therapy: success by design meets failure by efficacy. Molecular Therapy 22, 487-497
120. Cordero-Llana Ó et al. (2015) Enhanced efficacy of the CDNF/MANF family by combined intranigral overexpression in the 6-OHDA rat model of Parkinson's disease. Molecular Therapy 23, 244-254
121. Rickert M. et al. (2005) Adenovirus-mediated gene transfer of growth and differentiation factor-5 into tenocytes and the healing rat Achilles tendon. Connective Tissue Research 46, 175-183
122. Basile P. et al. (2008) Freeze-dried tendon allografts as tissueengineering scaffolds for Gdf5 gene delivery. Molecular Therapy 16, 466-473
123. O'Sullivan D.B., Harrison P.T. and Sullivan A.M. (2010) Effects of GDF5 overexpression on embryonic rat dopaminergic neurones in vitro and in vivo. Journal of Neural Transmission 117, 559-572
124. Zhu J. et al. (2012) Intranasal administration: A potential solution for cross-BBB delivering neurotrophic factors. Histology and Histopathology 27, 537-548
125. Lochhead J.J. and Thorne R.G. (2012) Intranasal delivery of biologics to the central nervous system. Advanced Drug Delivery Reviews 64, 614-628
126. Hanson L.R. et al. (2012) Intranasal delivery of growth differentiation factor 5 to the central nervous system. Drug Delivery 19, 149-154
127. Harkema J.R., Carey S.A. and Wagner J.G. (2006) The nose revisited: A brief review of the comparative structure, function, and toxicologic pathology of the nasal epithelium. Toxicologic Pathology 34, 252-269
128. Pervaiz S. and Irshad S. (2012) Role of nanobiotechnology in Parkinson's disease. Pakistan Journal of Biochemistry and Molecular Biology 34, 35-43
129. Kells A.P., Forsayeth J. and Bankiewicz K.S. (2012) Glialderived neurotrophic factor gene transfer for Parkinson's disease: Anterograde distribution of AAV2 vectors in the primate brain. Neurobiology of Disease 48, 228-235